Showing 4391-4400 of 5910 results for "".
- Amydis Enrolls First Participants in PROBE, a Phase 1/2a Trial Evaluating a Novel Retinal Tracer in People with Amyotrophic Lateral Sclerosis or Parkinson’s Diseasehttps://modernod.com/news/amydis-announces-enrollment-of-first-participants-in-probe-a-phase-12a-trial-evaluating-a-novel-retinal-tracer-in-people-with-amyotrophic-lateral-sclerosis-or-parkinsons-disease/2481109/Amydis announced dosing of the first patients in the company’s phase 1/2a trial evaluating AMDXP-2011P, a proprietary small molecule retinal imaging agent “retinal tracer” targeting deposits of alpha synuclein (ASYN) and the TAR DNA-binding protein 43 (TDP-43) in patients w
- Atsena Therapeutics Announces Late-Breaker Presentation at the AAO Annual Meetinghttps://modernod.com/news/atsena-therapeutics-announces-late-breaker-presentation-at-the-aao-annual-meeting/2481107/Atsena Therapeutics announced that data from the phase 1/2 clinical trial of ATSN-101 will be presented in a late breaking developments session during the Retina Subspecialty Day at the American Academy of Ophthalmology Annual Meeting (AAO 2022), which is being held Sept
- European Commission Approves Roche’s Vabysmo for Wet AMD and DMEhttps://modernod.com/news/european-commission-approves-roches-vabysmo-for-wet-amd-and-dme/2481102/Roche announced that the European Commission (EC) approved Vabysmo (faricimab) for the treatment of wet age-related macular degeneration (AMD) and visual impairment due to diabetic macular edema (DME). “Many people with nAMD and DME struggle to keep up with the mont
- Pixium Vision Reaches Enrollment Target in the European Pivotal Trial PRIMAverahttps://modernod.com/news/pixium-vision-reaches-enrollment-target-in-the-european-pivotal-trial-primavera/2481101/Pixium Vision SA announced the completion of patient enrollment in the PRIMAvera pivotal trial in atrophic dry age-related macular degeneration (AMD), also known as geographic atrophy. A total of 38 patients have been enrolled in the PRIMAvera study
- Shamir Glacier PLUS Metaform on 1.6 and 1.67 Now Availablehttps://modernod.com/news/shamir-glacier-plus-metaform-on-16-and-167-now-available/2481093/Shamir announced the availability of the new Glacier PLUS Metaform lens-coating technology, which uses fewer resources and chemicals in its production than its premium AR coating, making it an eco-friendly option for consumers. According to Shamir, features of the new len
- Glaukos Announces Positive Topline Outcomes in Two Phase 3 Pivotal Trials of iDose TRhttps://modernod.com/news/glaukos-announces-positive-topline-outcomes-for-both-phase-3-pivotal-trials-of-idose-tr/2481092/Glaukos announced positive topline data for both phase 3 pivotal trials of iDose TR that successfully achieved its prespecified primary efficacy endpoints through 3 months in both phase 3 trials and demonstrated excellent tolerability and a favorable safety profile through 1
- Bausch + Lomb Sponsored Visionary Report Spotlights Nation's 'Blind Spots' on AMDhttps://modernod.com/news/bausch-lomb-sponsored-visionary-report-spotlights-nations-blind-spots-on-amd/2481091/Bausch + Lomb released a report of survey results from the company’s first Visionary Report, which was designed to identify new key insights into the value Americans place on their eyesight, as well as the ‘blind spots’ that may exist in the understanding and aware
- Sight Sciences Announces Completion of Enrollment in SAHARA, a Randomized Clinical Trial of the TearCare System vs Restasishttps://modernod.com/news/sight-sciences-announces-completion-of-enrollment-in-sahara-a-randomized-clinical-trial-of-the-tearcare-system-vs-restasis/2481086/Sight Sciences announced the completion of enrollment in the SAHARA trial, a study designed to evaluate whether an interventional dry eye procedure with the TearCare System is superior in alleviating the signs and symptoms of dry eye disease compared to 6-months of twice daily Restasis&
- Ciliatech Presents New Concept in Glaucoma Implants, First to Bypass Opening Anterior Eye Chamberhttps://modernod.com/news/ciliatech-presents-new-concept-in-glaucoma-implants-first-to-bypass-opening-anterior-eye-chamber/2481085/Ciliatech, which is developing a new class of implant to treat glaucoma durably named
- Pixium Vision Announces Implantation of First Patient in Italy in Prima System European Pivotal Trial PRIMAverahttps://modernod.com/news/pixium-vision-announces-implantation-of-first-patient-in-italy-in-prima-system-european-pivotal-trial-primavera/2481084/Pixium Vision announced the successful first implantation of a patient in Italy in the PRIMAvera pivotal trial in atrophic dry age-related macular degeneration (dry AMD). This follows the approval of the PRIMAvera study by the Italian Ministry of Health and the opening of the first clinical